Episodios

  • ReconAfrica confirms hydrocarbon pay at Kavango West 1X well in Namibia

    ReconAfrica confirms hydrocarbon pay at Kavango West 1X well in Namibia
    Dec 3 2025
    Reconnaissance Energy Africa or ReconAfrica CEO Brian Reinsborough joined Steve Darling from Proactive to announce the results from the company’s Kavango West 1X exploration well, located on Petroleum Exploration Licence 73 in onshore Namibia. The well delivered encouraging results, encountering approximately 400 metres of gross hydrocarbon-bearing section within the Otavi carbonate interval, as identified by wireline logging data. Reinsborough told Proactive that detailed evaluation of the logs confirms 64 net metres of hydrocarbon pay, supported by both wireline interpretation and strong mud log anomalies. In addition, the company identified a further 61 metres (approximately 200 feet) of hydrocarbon shows in deeper intervals. These zones are interpreted to contain naturally fractured limestone reservoirs, a geological feature that could significantly enhance the flow potential and overall deliverability of hydrocarbons. Following these positive results, ReconAfrica’s forward program will now focus on comprehensive well testing to establish commercial flow rates from the most prospective intervals. The company will proceed with testing due to the strong indications of hydrocarbon-saturated reservoirs across multiple zones, based on the combined evidence from wireline logs, oil and gas shows, and interpreted natural fracture systems within the limestone units. A production test is planned to evaluate the deliverability characteristics of the key intervals within the Otavi carbonate section. The test will be conducted using 5-inch production casing and Tubing-Conveyed Perforations (TCP), allowing the company to selectively perforate specific pay zones. These selections will be based on intervals where hydrocarbon pay has been confirmed on wireline logs and where the most significant oil and gas shows were observed. Reinsborough noted that the upcoming testing phase represents an important next step in determining the commercial potential of the Kavango West 1X well and further advancing ReconAfrica’s exploration efforts across the broader Kavango Basin in Namibia. #proactiveinvestors #reconnaissanceenergyafricaltd #tsxv #reco #otcqx #recaf #NamibiaOil #ProspectI #OilExploration #EnergyUpdate #OnshoreDrilling #OilAndGasNews #AfricanEnergy #OilDiscovery #EnergyInvesting #OilExploration #NamibiaOil #EnergyInvesting #KavangoBasin #BrianReinsborough #OilAndGas #InvestorUpdate #ProactiveInvestors #AngolaEnergy
    Más Menos
    4 m
  • Tonix wins FDA clearance to launch phase 2 trial for major depressive disorder

    Tonix wins FDA clearance to launch phase 2 trial for major depressive disorder
    Dec 3 2025
    Tonix Pharmaceuticals Holdings CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug (IND) application for TNX-102 SL, enabling Tonix to begin clinical development of the drug for major depressive disorder (MDD) in adults. Dr. Lederman explained that the IND clearance allows Tonix to initiate the potentially pivotal Phase 2 HORIZON study — a 6-week, randomized, double-blind, placebo-controlled trial evaluating TNX-102 SL as a first-line monotherapy. The study will enroll approximately 360 adults across about 30 U.S. clinical sites. Participants must be 18 years or older and currently experiencing a moderate to severe major depressive episode. The trial will compare TNX-102 SL 5.6 mg, taken sublingually at bedtime, against placebo. The primary endpoint is change from baseline at Week 6 on the MADRS or Montgomery–Åsberg Depression Rating Scale total score. Secondary measures include global impression scores, anxiety assessments, and indicators of sleep disturbance. Tonix expects to begin enrolling patients in mid-2026. Dr. Lederman emphasized the significant need for new treatment options in MDD — a serious and widespread psychiatric condition affecting more than 21 million adults in the United States each year. Symptoms commonly include persistent sadness or loss of interest, sleep and appetite disruption, fatigue, impaired concentration, and feelings of worthlessness. These symptoms must be present for at least two weeks and cause meaningful impairment to daily life. Tonix aims to advance TNX-102 SL as a novel therapeutic option to address this substantial unmet medical need. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #kidneydisease #massachusettsgeneralhospital #massgeneral #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #DepressionTreatment #TNX102SL #MajorDepressiveDisorder #MentalHealthInnovation #SleepTherapy #FDAApproval #BiotechNews
    Más Menos
    3 m
  • Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial

    Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial
    Dec 3 2025
    Lantern Pharma CEO Panna Sharma joined Steve Darling from Proactive to discuss the company’s latest clinical milestone and its broader mission to transform oncology drug development through the use of artificial intelligence, machine learning, and genomic data. Lantern’s proprietary RADR® AI platform integrates billions of biological and clinical data points to identify predictive biomarkers, forecast drug response, and design more targeted and efficient clinical trials aimed at delivering precision cancer therapies to patients. The company announced additional details from its recently completed Phase 1a dose-escalation study of LP-184, its lead drug candidate. The trial produced encouraging results, demonstrating durable disease control in 63 heavily pre-treated patients with advanced solid tumors, many of which exhibited deficiencies in DNA damage repair pathways—an area where LP-184 is designed to be particularly effective. Sharma told Proactive that the Phase 1a study successfully met all primary endpoints for safety and tolerability, while also clearly establishing a recommended Phase 2 dose (RP2D). He emphasized that these outcomes validate both the scientific rationale behind LP-184 and the predictive capabilities of Lantern’s AI-driven development approach. Building on these positive results, Lantern Pharma is now advancing an ambitious precision oncology strategy that includes multiple biomarker-guided Phase 1b/2 clinical trials. These studies will target major cancer indications such as triple-negative breast cancer (TNBC), glioblastoma multiforme (GBM), non-small cell lung cancer, and advanced bladder cancer. The commercial potential for LP-184 is significant. Lantern and independent industry analysts estimate that the aggregate annual market opportunity for the drug across these and additional targeted indications could exceed $10 billion. Preclinical models have shown nanomolar potency, while early clinical data indicate encouraging durability of response even in heavily pre-treated patient populations. LP-184 has also received important regulatory recognition from the U.S. Food and Drug Administration, including Fast Track Designation for TNBC and GBM, as well as Orphan Drug Designation for malignant gliomas, pancreatic cancer, and atypical teratoid/rhabdoid tumors (ATRT). Sharma noted that these designations support an accelerated development pathway as Lantern continues to move LP-184 toward later-stage clinical trials. #proactiveinvestors #laternpharma #nasdaq #ltrn #LanternPharma #PannaSharma #PrecisionOncology #CancerResearch #AIinHealthcare #MachineLearning #Genomics #ClinicalTrials #BiotechNews #OncologyInnovation #LP184 #Phase1a #Phase2Trials #BiomarkerDriven #TripleNegativeBreastCancer #Glioblastoma #LungCancer #BladderCancer #OrphanDrug #FastTrackDesignation #FDA #PrecisionMedicine
    Más Menos
    7 m
  • Century Lithium reports breakthrough results in rare earth recovery from Angel Island project

    Century Lithium reports breakthrough results in rare earth recovery from Angel Island project
    Dec 3 2025
    Century Lithium CEO Bill Willoughby joined Steve Darling from Proactive to announce positive results from ongoing test work evaluating the recovery of rare earth elements (REEs) from primary lithium leach solutions generated at the company’s Angel Island lithium project in Nevada. Initial testing shows that high REE recoveries can be achieved without any negative impact on lithium recovery, marking a significant technical advancement for the project. Willoughby told Proactive that producing a secondary REE-rich product could materially strengthen the overall economics of the Angel Island project while also aligning the company with broader U.S. government and industry initiatives aimed at securing resilient North American critical-mineral supply chains. Century Lithium has previously confirmed that leach solutions derived from Angel Island claystone contain meaningful concentrations of several high-value rare earth elements, including dysprosium, gadolinium, neodymium, and praseodymium. The solutions also contain elevated levels of critical metals such as scandium, lanthanum, and cerium, along with the presence of cesium. Recent ion-exchange test work achieved greater than 97% recovery of the identified REEs and critical metals, excluding cesium, while maintaining complete selectivity against lithium. This lithium selectivity is essential for preserving the integrity of the company’s downstream lithium recovery process, which includes ultrafiltration, direct lithium extraction, and subsequent steps required to produce high-purity lithium carbonate. Willoughby emphasized that these results represent a major technical milestone, demonstrating that REE extraction and recovery can be integrated into the Angel Island flowsheet without compromising Century Lithium’s core lithium production process. Century Lithium believes these advancements position the company to potentially become a dual supplier of both lithium and rare earth elements to North American critical-mineral markets. Management noted that this dual-output capability could significantly enhance long-term project value, strengthen supply-chain resilience, and further support the strategic importance of Angel Island in the electrification and advanced manufacturing sectors. #proactiveinvestors #centurylithiumcorp #tsxv #lce #otcqx #cydvf #mining #oricaspecialtymining#rareearthmetals #ree #mining #AngelIsland #LithiumProject #RareEarthElements
    Más Menos
    4 m
  • Pantheon Resources reports early flowback at Dubhe-1 Well as clean-up operations continue

    Pantheon Resources reports early flowback at Dubhe-1 Well as clean-up operations continue
    Dec 3 2025
    Pantheon Resources CEO Max Easley and Chairman David Hobbs joined Steve Darling from Proactive to provide a detailed operational update on the company’s flagship Dubhe-1 well, outlining steady progress in well clean-up operations and encouraging early flowback performance in Alaska. Hobbs said the well is tracking firmly “within the envelope of expectation,” emphasizing that while it is still too early to draw definitive conclusions, operations to date have progressed smoothly and in line with technical forecasts. He stressed that further data will be required before firm performance metrics can be established, adding, “The well will speak,” underscoring the importance of patience as the reservoir continues to stabilize and respond. Additional operational updates are expected over the coming weeks as more flowback data is collected. Easley provided further insight into the early production phase, explaining that visible flaring began shortly after oil started flowing, with motorists along the Dalton Highway quickly noticing the flare. He confirmed that the flare has been continuous since flow commenced, indicating sustained production activity. Easley reiterated that the current phase is focused on well stabilization rather than peak output, with oil volumes gradually increasing in a manner consistent with expectations at this early stage. The company also revised its cost guidance for the Dubhe-1 well from the previously estimated $25 million to approximately $33 million. Easley explained that the increase was largely driven by additional appraisal-related initiatives undertaken during the program, including the drilling of a pilot hole to help confirm the scale of newly identified resources. This additional work is estimated to have contributed approximately 200 million barrels to Pantheon’s total resource base. Easley also highlighted the operational efficiency achieved by the drilling and completion team, noting that completion activities were executed in just seven days — a significant improvement compared to the 28 days required for similar operations in earlier projects. This reduction reflects advancements in planning, execution, and technical performance. Looking ahead, Hobbs said the company expects to reach approximately 50% flowback within the next two to three weeks, which will provide more meaningful insight into the well’s production behavior. Both Easley and Hobbs expressed confidence in the asset’s potential based on results observed so far and reiterated that the Dubhe-1 well remains a key catalyst in Pantheon Resources’ broader Alaskan development strategy. #proactiveinvestors #pantheonresourcesplc #mining #lse #panr #pthrf #Dubhe1 #AlaskaOil #OilAndGasDevelopment #EnergyStocks #NaturalGas #AlaskaEnergy #OilExploration #OilProduction #PantheonDrilling #InvestingInOil
    Más Menos
    5 m
  • EMV Capital portfolio company Wanda Health's virtual care tackles US chronic disease crisis

    EMV Capital portfolio company Wanda Health's virtual care tackles US chronic disease crisis
    Dec 3 2025
    EMV Capital (AIM:EMVC) CEO Dr Ilian Iliev and Tom Smith, CEO of EMV portfolio company Wanda Health, talked with Proactive's Stephen Gunnion about how the company is transforming virtual care for cardiometabolic diseases and weight management. Smith said Wanda has developed a new care model that integrates intelligent technology, connected devices, and coaching to deliver better patient outcomes and reduce dependence on expensive medications like GLP-1s. "We built a new model of virtual care designed specifically for cardiometabolic disease and weight management, areas where traditional medication-driven approaches have become too expensive and all too far reactive," Smith explained. He added that the company’s platform is gaining strong traction in the US healthcare market, particularly with health plans seeking to cut GLP-1 costs and improve chronic disease outcomes. Smith highlighted that the company’s strongest momentum is with US health plans, large employers, and chronic care providers. In 2025, Wanda launched a GLP-1 management program, scaled its coaching services, and released an insights engine for population health intelligence. Over the next 12 to 18 months, key revenue drivers are expected to include the expansion of GLP-1 cost-reduction programs, broader chronic disease pathways, and commercialisation of its analytics tools. Iliev noted that Wanda aligns with EMV's "Venture Build" program, emphasising its IP, real-world healthcare impact, and the adaptability of its business model. For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future updates. #DigitalHealth #VirtualCare #GLP1 #CardiometabolicHealth #WandaHealth #ChronicDisease #HealthTech #RemoteMonitoring #WeightManagement #USHealthcare #EMVCapital #HealthInnovation
    Más Menos
    10 m
  • EMV Capital portfolio company DeepTech Recycling: turning plastic waste back to oil

    EMV Capital portfolio company DeepTech Recycling: turning plastic waste back to oil
    Dec 3 2025
    EMV Capital (AIM:EMVC) CEO Dr Ilian Iliev and Marvine Besong, MD and CTO of EMV portfolio company DeepTech Recycling, talked with Proactive's Stephen Gunnion about the company's breakthrough plastic recycling technology and how it supports a circular economy. Besong explained that traditional recycling methods, such as mechanical recycling, often degrade the quality of plastics and can only process a narrow range of materials. In contrast, DeepTech Recycling uses a process that converts plastics back into oil. “This process can be repeated over and over again without the loss of quality,” he said. This approach allows for the creation of new, high-quality plastics from waste, significantly expanding the types of plastics that can be recycled and reused. The company is currently focusing on commercial applications in the plastic packaging sector, which accounts for around 40–45% of global plastic waste. Iliev said the company’s "Venture Build" program is centred on supporting IP-rich, disruptive technologies with scalable potential. He added that DeepTech Recycling’s capital-light structure, which separates project funding from core IP and licensing, offers potential for substantial non-dilutive returns to investors. Besong noted that the company is nearing final investment decisions on several commercial initiatives. The next 12 to 18 months are expected to include financial close and the launch of revenue-generating projects. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications so you never miss an update. #PlasticRecycling #CircularEconomy #DeepTechRecycling #SustainableTech #Cleantech #WasteToEnergy #PlasticWaste #GreenInvesting #EMVCapital #RecyclingInnovation
    Más Menos
    9 m
  • Panthera Eyes $1.58B India arbitration as U.S. investor interest grows

    Panthera Eyes $1.58B India arbitration as U.S. investor interest grows
    Dec 2 2025
    Panthera Resources CEO Mark Bolton joined Steve Darling from Proactive’s OTC Studio in New York City to discuss the company’s ongoing focus on international arbitration linked to its Bhukia Gold Project in India. Bolton explained that, while Panthera is fundamentally a gold exploration company with assets spanning West Africa and India, its primary value driver at present lies in its legal action under the Australia-India bilateral investment treaty. The company is pursuing a substantial $1.58 billion claim against the Indian government, positioning the arbitration as a potential game-changer for shareholder value. “The focus right now is essentially on pursuing a bilateral investment treaty claim and arbitration,” Bolton said, highlighting that the legal process has been ongoing for three years and is now well-advanced. A hearing has been scheduled for December 2026, with several procedural milestones already established. Bolton underscored that this timing could present a unique entry point for investors: “This is actually a really good time for investors to get involved,” he added. In addition to its legal pursuits, Panthera is actively increasing its visibility among U.S. investors. The company recently achieved a listing on the OTCQB under the ticker PATRF, a move driven by strong investor demand rather than corporate necessity, according to Bolton. Outside of the arbitration, Panthera continues to manage and develop its exploration assets in West Africa, with further updates expected as projects progress. The combination of ongoing litigation potential and core exploration operations, Bolton noted, provides multiple avenues for value creation for investors. #proactiveinvestors #aim #pat #otcqb #payrf #mining #westafrica #GoldExploration #BhukiaProject #MiningNews #IndiaArbitration #InvestorUpdate #GoldMining #OTCQB #MiningLitigation #WestAfricaMining #ProactiveInvestors
    Más Menos
    4 m